Similarly, gefitinib and erlotinib reduced vessel formation, decreased vascular permeability, and improved tumor oxygenation in xenograft models through the inhibition of HIF-1α and the production of angiogenic factors such as VEGF-A and IL-8 by tumor cells [216,217,218]. This evidence concerns the gene VEGFA and neoplasm.